SCHEDULE: Timothy P. Lynch Discloses 13% Stake in AEON Biopharma

Timothy P. Lynch has filed a Schedule 13G, reporting beneficial ownership of 6,500,000 shares, representing 13.0% of AEON Biopharma's Class A Common Stock.

Summary

• Timothy P. Lynch has reported beneficial ownership of 6,500,000 shares of AEON Biopharma, Inc. Class A Common Stock.
• This ownership stake represents 13.0% of the total outstanding shares.
• The filing is a Schedule 13G, indicating the shares were not acquired for the purpose of influencing control of the issuer.
• The reported shares exclude prefunded warrants and milestone warrants, which have limitations on exercise based on beneficial ownership thresholds (4.99%).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily due to the disclosure of a significant ownership stake, but with limitations on immediate control due to warrant restrictions.

Positives

• Timothy P. Lynch has acquired a substantial ownership stake of 13.0% in AEON Biopharma, Inc.
• The filing indicates a clear and direct beneficial ownership of 6,500,000 shares.

Negatives

• The ability to exercise prefunded and milestone warrants is currently restricted, preventing further increases in beneficial ownership beyond 4.99% without triggering reporting requirements.
• The filing explicitly states the securities were not acquired for the purpose of influencing control, suggesting a passive investment stance.

Risks

• The exercise of warrants is capped at 4.99% beneficial ownership, limiting the potential for increased influence or control through these instruments.
• The filing is based on the outstanding share count reported as of June 30, 2026, and any subsequent changes in outstanding shares could alter the percentage ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of current ownership status.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. The significant percentage disclosed by Timothy P. Lynch suggests a notable investor in AEON Biopharma, but the limitations on warrant exercise imply a strategy focused on a specific investment level rather than active control or a rapid increase in stake.

Stakeholder Impact

• Shareholders: The disclosure of a significant 13.0% stake by a single investor may be viewed positively, indicating confidence in the company, but the passive nature and warrant limitations suggest it may not lead to immediate strategic shifts.
• Management: May need to engage with this significant shareholder, although the passive filing suggests no immediate pressure for control changes.

Next Steps

• Monitor future filings for any changes in Timothy P. Lynch's ownership stake or exercise of warrants.
• Observe AEON Biopharma's performance and strategic developments that may influence investor sentiment and warrant exercise decisions.

Key Dates

Recommendation

The filing indicates a significant passive ownership stake. While 13.0% is substantial, the explicit statement that securities were not acquired for control and the limitations on warrant exercise suggest a 'hold' rather than an immediate 'buy' or 'sell' based solely on this disclosure. Further analysis of AEON Biopharma's fundamentals and strategic direction is required for a more definitive recommendation.

Keywords

AEON Biopharma, Schedule 13G, Beneficial Ownership, Timothy P. Lynch, Class A Common Stock, Warrants, Shareholder